2023年第28届欧洲血液学协会大会（EHA）将于2023年6月8日至11日在德国法兰克福召开。EHA 2023很高兴能在现场欢迎来自全球的血液学家，同时EHA 2023也将于会议期间在EHA大会平台上进行直播。

本届EHA大会将聚焦血液学研究的最新前沿进展并邀请行业极富盛名的专家和学者做主题演讲，快来看看都有哪些重磅研究吧！

ALL

摘要号：S116

报告人：潘静

onor-derived cd5 car t cells for t-cell acute lymphoblasticleukemia

供体来源的CD5 CAR-T细胞用于T细胞急性淋巴细胞白血病治疗

摘要号S113

报告人：蔡梓红

Impact of IKZF1 Deletion In Relapsed and/or Refractory B-Cell Acute Lymphoblastic Leukemia Treated with CD19-Chimeric Antigen Receptor T-Cell Therapy

IKZF1缺失对于CD19嵌合抗原受体T（CAR-T）细胞治疗复发和/或难治性（R/R）急性B淋巴细胞白血病（B-ALL）的影响

摘要号S118

报告人：Dr. Nicholas Short

A chemotherapy-free combination of ponatinib andblinatumomab for patients with newly diagnosed philadelphiachromosome-positive acute lymphoblastic leukemia: subgroupanalysis from a phase Ⅱ study

普纳替尼和布利妥莫单抗无化疗组合用于新诊断ph阳性急性淋巴细胞白血病患者：一项II期研究的亚组分析结果

AML

摘要号S132

报告人：Juan Miguel Bergua Burgues

updated results of ven-a-qui study: a phase 1-2 trial to assessthe safety and efficacy of triplets for newly diagnosed unfit amlpatients: azacitidine or low-dose cytarabine with venetoclax andquirzatinib

Ven-a-qui研究的最新结果：一项Ⅰ/Ⅱ期试验，评估新诊断AML患者阿扎胞苷或低剂量阿糖胞苷与venetoclax和奎扎替尼三联疗法的安全性和有效性

摘要号S133

报告人：Dr. Harry Gill

an entirely oral regimen of oral-ato, atra and ascorbic acid inrisk-adapted treatment of newly-diagnosed apl resulted in excellentclinical/molecular responses with durable remission

三氧化二砷、全反式维甲酸和维生素C全口服方案治疗新诊断APL获得良好的临床缓解

摘要号S138

报告人：Marius Bill

validation of the revised 2022 european leukemianet (eln) riskstratification in adult patients with acute myeloid leukemia

修订后的2022年欧洲白血病网络（ELN）风险分级在成人AML中的验证情况

侵袭性非霍奇金淋巴瘤

摘要号S227

报告人：Sirpa Leppä

nitial safety data from the phase 3 polar bear trial in elderlyor frail patients with diffuse large cell lymphoma, comparing R-pola-mini-CHP and R-mini-CHOP

老年或虚弱弥漫性大细胞淋巴瘤患者中R-pola-mini-CHP VS R-mini-CHOP Polar Ⅲ期试验初步安全数据

摘要号S234

报告人：张毅

updated clinical results of first-in-human study of cd19/bcmadual-targeting fast car-t gc012f for patients withrelapsed/refractory b-cell non-hodgkin’s lymphoma

CD19/BCMA双靶向快速CAR-T GC012F治疗复发/难治性B细胞非霍奇金淋巴瘤患者的首次人体研究的最新临床结果

摘要号S230

报告人：Matthew J. Frank

CD22 CAR-T cell therapy is safe and effective in patients withlarge b cell lymphoma who have relapsed after CD19 CAR-T cell therapy

CD22 CAR T 细胞疗法对 CD19 CAR -T 细胞治疗后复发的大B细胞淋巴瘤患者安全有效

CML

摘要号S158

报告人：江倩

efficacy of low-dose tyrosine kinase inhibitor therapy afterachieving major molecular response in persons with chronic myeloidleukaemia

慢性粒细胞白血病患者实现主要分子应答后低剂量酪氨酸激酶抑制剂治疗的疗效

未完待续......

Tags： EHA 2023 即将开启！血液肿瘤领域重磅研究汇总，一文尽览！